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Significance statementThe present review examines work reporting simple limbal epithelial transplantation (SLET), an innovative technique that uses minimal limbal tissue from the healthy eye to regenerate the cornea in the limbal deficient diseased eye. Results since the introduction of SLET in 2012 suggest that the success rate is comparable to established techniques, conjunctival‐limbal autograft and cultured limbal epithelial transplantation. However, SLET has the advantages of requiring a smaller biopsy, achieving harvest and transplantation in a single operation, and the unnecessity of cell culture laboratories. AlloSLET, a novel modification of SLET using allogeneic tissue, promises to further improve outcome through promotion of early resolution of inflammation in the injured/diseased eye.

1. INTRODUCTION {#sct312634-sec-0003}
===============

The corneal epithelium is renewed by stem cells located in specialized niches in the limbus at the cornea‐conjunctiva junction. Loss or damage to the limbal stem cell pool can lead to limbal stem cell deficiency (LSCD), where homeostatic maintenance of the corneal epithelium is compromised, leading to ingrowth of the conjunctiva. Etiology includes autoimmune diseases (Steven‐Johnson syndrome), infections (trachoma), contact lens wear, and thermal/alkali burns. LSCD may be partial or total depending on the extent of the damage.[1](#sct312634-bib-0001){ref-type="ref"} Conjunctivalization is pathogenic for LSCD and is frequently accompanied by inflammation, neovascularization, persistent epithelial defects, and scarring resulting in decreased vision or blindness.

Several surgical and stem cell‐based treatments for LSCD have been developed over the last decades.[1](#sct312634-bib-0001){ref-type="ref"} Simple limbal epithelial transplantation (SLET) is a new treatment strategy introduced by Sangwan et al.[2](#sct312634-bib-0002){ref-type="ref"} In this technique a small limbal biopsy is harvested from the healthy eye. The biopsy is divided into minute explant pieces that are distributed over human amniotic membrane (AM) and glued to the cornea (Figure [1](#sct312634-fig-0001){ref-type="fig"}). Outgrowth from individual explants merges with neighboring explant growth.[4](#sct312634-bib-0004){ref-type="ref"} Reepithelialization is typically achieved within 2 weeks. This review summarizes 404 cases in 31 clinical studies using SLET to date.

![Illustration of 2‐year outcomes following the use of simple limbal epithelial transplantation (SLET) for treatment of patients with partial and total limbal stem cell deficiency (LSCD). A‐J, Patients with partial LSCD following ocular burns: A‐F, Preoperative photographs and F‐J, 2‐year postoperative photographs showing a completely epithelized and stable corneal surface. K‐U, Patients with total LSCD: K‐O, Preoperative clinical photographs. P‐T, 2‐year postoperative photographs after SLET using Slit‐lamp photography. Images reprinted from Basu et al[3](#sct312634-bib-0003){ref-type="ref"}](SCT3-9-316-g001){#sct312634-fig-0001}

2. CURRENT OPTIONS FOR TREATMENT OF LSCD {#sct312634-sec-0004}
========================================

Reepithelialization of the corneal surface and improved visual acuity are the primary and secondary aims in treating LSCD. Currently, there are two main surgical techniques available using autologous limbal tissue; conjunctival‐limbal autograft (CLAU), and cultured limbal epithelial transplantation (CLET). In the CLAU technique two conjunctival‐limbal biopsies are harvested (120° cornea circumference each as described in the original CLAU technique) and transferred directly to the affected limbal deficient eye.[5](#sct312634-bib-0005){ref-type="ref"} Thus, an advantage of this procedure is that it does not require the use of a transplant substrate, saving the expense of using AM. Published reviews summarizing results of CLAU report a success rate of between 80% and 100% and improvement in visual acuity of 25% and 100%, with a survival rate of 62% at 6‐year follow‐up.[6](#sct312634-bib-0006){ref-type="ref"}, [7](#sct312634-bib-0007){ref-type="ref"}

The CLET technique depends on the culture of limbal biopsies to produce limbal cell sheets prior to transplantation.[8](#sct312634-bib-0008){ref-type="ref"} The introduction of the CLET procedure by Pellegrini et al. in 1997 offered a significant advantage over CLAU by harvest of a smaller amount of limbal tissue, minimizing the risk of iatrogenic injury to the healthy eye.[8](#sct312634-bib-0008){ref-type="ref"} Meta‐analysis shows successful reepithelialization in 72% (n = 720) of cases and improved visual acuity in 63% (n = 539) of cases reporting the use of the standard CLET technique.[9](#sct312634-bib-0009){ref-type="ref"} This technique has been criticized for use of mouse cells and other xenogeneic components in preparation of the cultured sheets, potentially resulting in infection and quality variation.[10](#sct312634-bib-0010){ref-type="ref"} However, it is possible to substitute AM for mouse feeder cells.[11](#sct312634-bib-0011){ref-type="ref"}, [12](#sct312634-bib-0012){ref-type="ref"} As evidence of its safety, in 2015, the CLET technique advanced to become the first stem cell‐based therapy to receive approval for application throughout the European Union (EU) under the trade name "Holoclar".[13](#sct312634-bib-0013){ref-type="ref"}

Several non‐limbal cell types have also shown promise in treating LSCD, offering options for treatment of bilateral LSCD using autologous cells and avoiding immunosuppression.[14](#sct312634-bib-0014){ref-type="ref"} Among alternatives, the cultured oral mucosal epithelial transplantation (COMET) technique has been most widely reported.[15](#sct312634-bib-0015){ref-type="ref"} Use of this tissue allows treatment of patients with Stevens‐Johnson syndrome.[16](#sct312634-bib-0016){ref-type="ref"} The success rate for COMET is comparable to CLET, resulting in reepithelialization in 63% (n = 230) of reported cases and improved visual acuity in 68% (n = 202).[17](#sct312634-bib-0017){ref-type="ref"}

2.1. Current challenges in treatment of LSCD {#sct312634-sec-0005}
--------------------------------------------

Though complications are rare and reepithelialization of the donor site usually occurs, the risk associated with taking two large limbal biopsies from the healthy donor eye is a concern associated with CLAU.[18](#sct312634-bib-0018){ref-type="ref"}, [19](#sct312634-bib-0019){ref-type="ref"}, [20](#sct312634-bib-0020){ref-type="ref"} The CLET and COMET techniques address this challenge but require production of cultured sheets in a good manufacturing practice‐regulated laboratory, which is expensive and limits accessibility. The COMET technique is promising, but peripheral neovascularization following surgery has been reported in many cases.[16](#sct312634-bib-0016){ref-type="ref"} The use of anti‐angiogenic agents in concert with COMET has shown benefit. However, inhibition of vascular endothelial growth factor has been shown to affect the overall wound healing response and induce corneal melt.[21](#sct312634-bib-0021){ref-type="ref"}

SLET offers several advantages compared with the above options: (a) risk of iatrogenic damage to the donor eye is reduced; (b) a small biopsy means the procedure can be repeated if necessary; (c) SLET does not require expensive specialized culture facilities; and (d) The SLET procedure can be performed in one operation streamlining patient care, resource management, and reducing costs. Results of a recent study involving 125 patients show that SLET can be successfully used to treat partial and total LSCD (Figure [1](#sct312634-fig-0001){ref-type="fig"}).[3](#sct312634-bib-0003){ref-type="ref"}

Treatment of bilateral LSCD remains a challenge. In addition to COMET, conjunctival‐limbal allografts from a living‐related relative (lr‐CLAL) or cadaveric tissue (keratolimbal allograft \[KLAL\]) are options. There have been two reports of modified SLET using allogeneic limbal tissue (alloSLET) to treat bilateral LSCD. AlloSLET compared with lR‐CLAL and KLAL procedures have so far not been directly compared. Regardless of the procedure, systemic immunosuppressants are critical for survival of allograft tissue.[22](#sct312634-bib-0022){ref-type="ref"}, [23](#sct312634-bib-0023){ref-type="ref"} A standard of care and recommended duration of immunosuppressants necessary to prevent allograft rejection has yet to be defined.[22](#sct312634-bib-0022){ref-type="ref"} Large studies reporting KLAL and lr‐CLAL procedures suggest an average duration of 42[24](#sct312634-bib-0024){ref-type="ref"}‐44[25](#sct312634-bib-0025){ref-type="ref"} months, whereas the only large study reporting alloSLET for bilateral LSCD recommends gradual reduction over 2 years followed by the indefinite use of systemic and topical immunosuppressants.[23](#sct312634-bib-0023){ref-type="ref"} Patients should be monitored for adverse systemic effects while taking immunosuppressants, which may include hypertension, diabetes mellitus, and biochemical abnormalities.[22](#sct312634-bib-0022){ref-type="ref"}

3. CHARACTERISTICS OF SLET STUDIES {#sct312634-sec-0006}
==================================

The present review is based on a search of the National Library of Medicine (PubMed) database using the term "simple limbal epithelial transplantation" that gave a list of 31 publications reporting pre‐clinical results of SLET (Table [S1](#sct312634-supitem-0001){ref-type="supplementary-material"}) and one publication optimizing the SLET technique.[26](#sct312634-bib-0026){ref-type="ref"}

As of August 2019, 404 cases of SLET were reported. The eight largest case series\' reported treatment of 125,[3](#sct312634-bib-0003){ref-type="ref"} 68,[27](#sct312634-bib-0027){ref-type="ref"} 30,[28](#sct312634-bib-0028){ref-type="ref"} 30,[29](#sct312634-bib-0029){ref-type="ref"} 30,[23](#sct312634-bib-0023){ref-type="ref"} 18,[30](#sct312634-bib-0030){ref-type="ref"} 15,[31](#sct312634-bib-0031){ref-type="ref"} and 11[32](#sct312634-bib-0032){ref-type="ref"} eyes. These included the largest prospective study to date, with 125 patients and a follow‐up period of at least 1 year[3](#sct312634-bib-0003){ref-type="ref"} and a multicenter international study of 68 patients.[27](#sct312634-bib-0027){ref-type="ref"} The remaining 23 studies were noncomparative single case studies or case series of 10 eyes or less.[2](#sct312634-bib-0002){ref-type="ref"}, [4](#sct312634-bib-0004){ref-type="ref"}, [33](#sct312634-bib-0033){ref-type="ref"}, [34](#sct312634-bib-0034){ref-type="ref"}, [35](#sct312634-bib-0035){ref-type="ref"}, [36](#sct312634-bib-0036){ref-type="ref"}, [37](#sct312634-bib-0037){ref-type="ref"}, [38](#sct312634-bib-0038){ref-type="ref"}, [39](#sct312634-bib-0039){ref-type="ref"}, [40](#sct312634-bib-0040){ref-type="ref"}, [41](#sct312634-bib-0041){ref-type="ref"}, [42](#sct312634-bib-0042){ref-type="ref"}, [43](#sct312634-bib-0043){ref-type="ref"}, [44](#sct312634-bib-0044){ref-type="ref"}, [45](#sct312634-bib-0045){ref-type="ref"}, [46](#sct312634-bib-0046){ref-type="ref"}, [47](#sct312634-bib-0047){ref-type="ref"}, [48](#sct312634-bib-0048){ref-type="ref"}, [49](#sct312634-bib-0049){ref-type="ref"}, [50](#sct312634-bib-0050){ref-type="ref"}, [51](#sct312634-bib-0051){ref-type="ref"}, [52](#sct312634-bib-0052){ref-type="ref"} One study directly compared SLET with CLAU, with 10 patients randomly assigned to each group.[33](#sct312634-bib-0033){ref-type="ref"} The Sangwan group in India published the most studies.[2](#sct312634-bib-0002){ref-type="ref"}, [3](#sct312634-bib-0003){ref-type="ref"}, [27](#sct312634-bib-0027){ref-type="ref"}, [29](#sct312634-bib-0029){ref-type="ref"}, [35](#sct312634-bib-0035){ref-type="ref"}, [42](#sct312634-bib-0042){ref-type="ref"}, [43](#sct312634-bib-0043){ref-type="ref"}, [44](#sct312634-bib-0044){ref-type="ref"}, [45](#sct312634-bib-0045){ref-type="ref"}, [46](#sct312634-bib-0046){ref-type="ref"}, [47](#sct312634-bib-0047){ref-type="ref"}, [48](#sct312634-bib-0048){ref-type="ref"}, [49](#sct312634-bib-0049){ref-type="ref"} Other centers in India,[4](#sct312634-bib-0004){ref-type="ref"}, [23](#sct312634-bib-0023){ref-type="ref"}, [28](#sct312634-bib-0028){ref-type="ref"}, [30](#sct312634-bib-0030){ref-type="ref"}, [31](#sct312634-bib-0031){ref-type="ref"}, [32](#sct312634-bib-0032){ref-type="ref"}, [33](#sct312634-bib-0033){ref-type="ref"}, [39](#sct312634-bib-0039){ref-type="ref"}, [40](#sct312634-bib-0040){ref-type="ref"}, [41](#sct312634-bib-0041){ref-type="ref"}, [51](#sct312634-bib-0051){ref-type="ref"}, [52](#sct312634-bib-0052){ref-type="ref"} England,[38](#sct312634-bib-0038){ref-type="ref"} Brazil,[36](#sct312634-bib-0036){ref-type="ref"} Mexico,[34](#sct312634-bib-0034){ref-type="ref"} Thailand,[50](#sct312634-bib-0050){ref-type="ref"} and the United States[37](#sct312634-bib-0037){ref-type="ref"} also contributed.

4. ETIOLOGY OF CASES TREATED WITH SLET {#sct312634-sec-0007}
======================================

Grading LSCD severity is important since some cases of partial LSCD may not require stem cell transplant.[53](#sct312634-bib-0053){ref-type="ref"}, [54](#sct312634-bib-0054){ref-type="ref"} SLET was mainly used in the treatment of adults and children with uniocular total and partial LSCD resulting from burns and chemical injuries (Table [S1](#sct312634-supitem-0001){ref-type="supplementary-material"}). Patients with unilateral LSCD and a clinically non‐inflamed wet ocular surface are ideal candidates for SLET[3](#sct312634-bib-0003){ref-type="ref"}, [37](#sct312634-bib-0037){ref-type="ref"} Preliminary reports also indicate that SLET has potential for use in non‐LSCD ocular diseases; ocular surface squamous neoplasia (OSSN) (9 eyes),[35](#sct312634-bib-0035){ref-type="ref"}, [41](#sct312634-bib-0041){ref-type="ref"}, [51](#sct312634-bib-0051){ref-type="ref"} laryngo‐onycho‐cutaneous syndrome (1 eye),[39](#sct312634-bib-0039){ref-type="ref"} pterygium (9 eyes),[34](#sct312634-bib-0034){ref-type="ref"} and recurrent pterygium (4 eyes) if results are confirmed in larger studies.[55](#sct312634-bib-0055){ref-type="ref"} However, pterygium can be treated using pterygium extended removal followed by autologous extended conjunctival grafting, which has a high success rate and is safe, simple, and fast to perform.[56](#sct312634-bib-0056){ref-type="ref"}

It has been shown that SLET can be used in patients with LSCD following failure of treatment with CLET.[29](#sct312634-bib-0029){ref-type="ref"} At a mean follow‐up of 2.3 years, 80% of the 30 eyes treated by SLET maintained a successful outcome without complications. Bilateral autoimmune diseases such as Steven‐Johnsons syndrome and ocular cicatricial pemphigoid are contraindications for SLET using autologous tissue. A recent study also showed that scleral ischemia resulting from chemical injury is a poor prognostic indicator for success using SLET.[31](#sct312634-bib-0031){ref-type="ref"}

SLET using biopsies of contralateral autologous tissue is most common. Although larger studies are necessary before recommendations can be made, recent case studies show the use of alloSLET for treatment of LSCD with a range of etiologies including extreme dry eye,[40](#sct312634-bib-0040){ref-type="ref"} chemical injury,[47](#sct312634-bib-0047){ref-type="ref"} and iatrogenic LSCD induced by mitomycin treatment for conjunctival melanoma.[38](#sct312634-bib-0038){ref-type="ref"} Iyer et al. also suggested innovative use of alloSLET as an acute temporary biological bandage.[30](#sct312634-bib-0030){ref-type="ref"} The goal of this treatment was to provide immediate stabilization of the wound environment, minimize more serious damage, and prepare the wound for future SLET using autologous tissue.

5. THE SLET TECHNIQUE {#sct312634-sec-0008}
=====================

Most studies used the original autologous SLET technique described by Sangwan et al. harvesting a small biopsy of limbal tissue from the healthy eye.[2](#sct312634-bib-0002){ref-type="ref"} In summary, the injured eye is prepared with a 360° peritomy, and the vascular pannus covering the cornea is removed (Figure [S1](#sct312634-supitem-0001){ref-type="supplementary-material"}). The eye is covered by AM to the extent of the peritomy, secured with fibrin glue (Figure [S1](#sct312634-supitem-0001){ref-type="supplementary-material"}A). A small 2 × 2 mm biopsy (30° cornea circumference) is excised from the superior limbus of the healthy eye and placed in a balanced salt solution (Figure [S1](#sct312634-supitem-0001){ref-type="supplementary-material"}B). The limbal tissue biopsy is subsequently cut into tiny pieces that are fixed onto the AM epithelial side up in a circular arrangement (avoiding the visual axis) using fibrin glue (Figure [S1](#sct312634-supitem-0001){ref-type="supplementary-material"}C). A soft bandage contact lens is then applied along with topical antibiotics and corticosteroids for the first week or until healed (Figure [S1](#sct312634-supitem-0001){ref-type="supplementary-material"}D). A second layer of AM instead of the contact lens can also be used.[37](#sct312634-bib-0037){ref-type="ref"}, [55](#sct312634-bib-0055){ref-type="ref"} Use of cryopreserved AM instead of fresh AM has been shown to be equally effective and allows the use of this procedure in the United States.[37](#sct312634-bib-0037){ref-type="ref"} Partial LSCD can be treated using a modified SLET technique, where superficial keratectomy is performed only in areas of fibrovascular pannus, thus avoiding the intact limbus areas.[3](#sct312634-bib-0003){ref-type="ref"}, [28](#sct312634-bib-0028){ref-type="ref"}

The SLET procedure has also been used as a preventative measure against development of LSCD. Wide excisional biopsies of ocular surface squamous neoplasia and SLET can be performed in the same procedure to prevent LSCD after resection.[35](#sct312634-bib-0035){ref-type="ref"}, [41](#sct312634-bib-0041){ref-type="ref"}

When severe stromal opacification is present, patients will additionally require penetrating keratoplasty (PK). It is sometimes necessary to perform PK simultaneously with SLET if patients are unwilling to undergo a second operation.[27](#sct312634-bib-0027){ref-type="ref"} Results from the three largest studies point to a correlation of failure with simultaneous performance of PK with SLET.[3](#sct312634-bib-0003){ref-type="ref"}, [27](#sct312634-bib-0027){ref-type="ref"}, [28](#sct312634-bib-0028){ref-type="ref"} Furthermore, SLET improves the corneal environment, which may promote self‐clearing of the stroma.[3](#sct312634-bib-0003){ref-type="ref"}, [28](#sct312634-bib-0028){ref-type="ref"} Therefore, delaying PK for at least a year post‐SLET is recommended. In support of this, a large multicenter study reported an overall success rate of 84% (n = 68), but this dropped to 20% in the eight eyes receiving simultaneous PK and SLET.[27](#sct312634-bib-0027){ref-type="ref"} However, the authors cautioned that the unsuccessful cases may have presented with more serious etiology. Singh et al. described performance of deep anterior lamellar keratoplasty in pediatric patients 9--15 months post‐SLET giving visual improvement of 64% (n = 11).[32](#sct312634-bib-0032){ref-type="ref"}

Failure of SLET is correlated with regeneration of the cornea by migrating conjunctival cells.[50](#sct312634-bib-0050){ref-type="ref"} Thus, in vivo confocal microscopy and impression cytology can be useful in determining the phenotype of regenerated epithelium on the cornea, allowing early diagnostic assessment of failure and management before clinical symptoms appear.[50](#sct312634-bib-0050){ref-type="ref"}

6. MECHANISM OF REGENERATION {#sct312634-sec-0009}
============================

The success of SLET is in large part attributed to in vivo expansion of transplanted explants on the corneal surface. However, the exact mechanism in terms of the individual contribution of fibrin glue, AM, limbal biopsy size, distribution of the biopsies, preexisting stem cells, and migration pattern of transplanted cells is as yet unknown. Detailed discussion of the role of these factors in reestablishing an epithelialized cornea is beyond the scope of the present review. The proposed benefits of the major components, fibrin glue and AM, and the source of proliferating stem cells will be briefly discussed here.

Fibrin glue was first reported as a replacement for sutures in an AM transplantation (AMT) procedure in 11 patients with partial LSCD.[57](#sct312634-bib-0057){ref-type="ref"} Here, reepithelialization was achieved through growth from residual limbal and corneal tissue, without the need to transplant limbal cells. Kheirkhah and colleagues suggested that the glue forms a full contact seal between the transplanted AM and the corneal surface, ensuring reepithelialization occurs on the surface of the AM rather than underneath, taking full advantage of the AM microenvironment.[57](#sct312634-bib-0057){ref-type="ref"} in vitro work has shown that fibrin glue inhibits cell migration, which in SLET may prevent ingrowth of conjunctival tissue at a critical phase and promote expansion of epithelial cells from explants on the AM surface.[58](#sct312634-bib-0058){ref-type="ref"} Growth rates vary between explants from the same donor placed in the same eye, which may be attributed to the amount of fibrin glue used for their individual attachment or to differences in handling during transplant.[4](#sct312634-bib-0004){ref-type="ref"} Fibrin glue has also been shown to extend the beneficial effects of AM by delaying its breakdown compared with sutures.[7](#sct312634-bib-0007){ref-type="ref"}, [57](#sct312634-bib-0057){ref-type="ref"}

The main benefit of AM is in its early application to control inflammation. It provides a substrate to promote the formation of a well‐differentiated stratified corneal epithelium.[59](#sct312634-bib-0059){ref-type="ref"} The advantage of the addition of limbal tissue in SLET (compared with AM alone as used in the AMT procedure) is highlighted where limbal explants have been lost postoperatively, resulting in failure of SLET despite the presence of AM.[3](#sct312634-bib-0003){ref-type="ref"} Amescua et al. used ultra‐high‐resolution optical coherence tomography to reveal that the transplanted AM persisted at least 4 months post‐SLET (in one patient).[37](#sct312634-bib-0037){ref-type="ref"}

The relative contribution of transplanted cells and residual surviving stem cells to the regenerated epithelium is unknown. A stable source of proliferating stem cells is necessary to restore long‐term homeostasis of the corneal epithelium. These may be established through transplanted stem cells becoming embedded or by dormant residual stem cells becoming reactivated. It is possible that in some cases removal of fibrotic tissue and paracrine signals from transplanted explants is sufficient to stimulate residual stem cells to resume their homeostatic function. Preliminary investigation to resolve these questions has revealed the presence of focal points of basal layer cells expressing putative markers for stem cells (ΔNp63α and ABCG2) post‐SLET[3](#sct312634-bib-0003){ref-type="ref"}; the presence of a mix of patient and donor cells on the cornea several months post‐alloSLET[30](#sct312634-bib-0030){ref-type="ref"}; and patches of outgrowth emerging from individual explants growing in a centripetal pattern that eventually merge with outgrowth from neighboring explants.[37](#sct312634-bib-0037){ref-type="ref"} Although it is clear that the role of transplanted cells needs further investigation in larger studies, these initial analyses suggest that the rapid reepithelialization seen post‐SLET can be attributed, at least in part, to transplanted proliferating cells from limbal explants.

7. RESULTS {#sct312634-sec-0010}
==========

Most studies used reversal of the main features of LSCD as the primary measure of success. This is defined as complete reepithelialization, a clinically stable corneal epithelium and reversal of vascularization.[60](#sct312634-bib-0060){ref-type="ref"} Improved visual acuity was used as a secondary definition of success. Reported follow‐up periods ranged from 6 to 59 months. Failure usually occurred within 6 months of surgery (Table [1](#sct312634-tbl-0001){ref-type="table"}). Combined results show that 83% (n = 336) of SLET operations were successful by the primary criterion and visual acuity improved in 69% of cases (n = 258) (Table [1](#sct312634-tbl-0001){ref-type="table"}). Summarizing results by severity, the success rates were 74.2% (n = 35) for partial LSCD and 76.8% (n = 151) for total LSCD (Table [1](#sct312634-tbl-0001){ref-type="table"}).

###### 

Outcomes of studies using simple limbal epithelial transplantation (SLET)

+----+-------------------------------------------------------------+-----------------------------------------------------------------------------+-----------------------+-------------------------------------------+--------------------------------------------------------------------------------------------------------------------------+-----------------------------------------------------------------------------------------------------------+------------------------------------------------------------------+
|    | References                                                  | Surgery                                                                     | No. of patients       | Stable corneal epithelium %               | Improvement in visual acuity %                                                                                           | Complications in recipient eye                                                                            | Follow‐up period                                                 |
+:===+:============================================================+:============================================================================+:======================+:==========================================+:=========================================================================================================================+:==========================================================================================================+:=================================================================+
| 1  | Shanbhag et al.[23](#sct312634-bib-0023){ref-type="ref"}    | AlloSLET: Living‐related alloSLET ×16                                       | 30                    | 83.3% (25/30)                             | 60% (18/30)                                                                                                              |                                                                                                           | Median 28 months (range, 13‐66 months)                           |
|    |                                                             |                                                                             |                       |                                           |                                                                                                                          |                                                                                                           |                                                                  |
|    |                                                             | Cadaveric ×14                                                               |                       | 14/16 (87.5%) in Living‐related           |                                                                                                                          |                                                                                                           |                                                                  |
|    |                                                             |                                                                             |                       |                                           |                                                                                                                          |                                                                                                           |                                                                  |
|    |                                                             |                                                                             |                       | 11/14 (78.6%) in cadaveric                |                                                                                                                          |                                                                                                           |                                                                  |
+----+-------------------------------------------------------------+-----------------------------------------------------------------------------+-----------------------+-------------------------------------------+--------------------------------------------------------------------------------------------------------------------------+-----------------------------------------------------------------------------------------------------------+------------------------------------------------------------------+
| 2  | Prabhasawat et al.[50](#sct312634-bib-0050){ref-type="ref"} | SLET ×5                                                                     | 10 eyes in 9 patients | 70% (7/10)                                | 70% (7/10)                                                                                                               | Failure: Central/peripheral neovascularization correlated with regrowth by conjunctival cells ×3          | 3‐18 months                                                      |
|    |                                                             |                                                                             |                       |                                           |                                                                                                                          |                                                                                                           |                                                                  |
|    |                                                             | Living‐related alloSLET ×5                                                  |                       |                                           | Ranging within improvement to 6/60 or better from HM                                                                     |                                                                                                           |                                                                  |
+----+-------------------------------------------------------------+-----------------------------------------------------------------------------+-----------------------+-------------------------------------------+--------------------------------------------------------------------------------------------------------------------------+-----------------------------------------------------------------------------------------------------------+------------------------------------------------------------------+
| 3  | Gupta et al.[31](#sct312634-bib-0031){ref-type="ref"}       | SLET 6 months later ×15                                                     | 7 x non‐isch.         | 75% (6/8) in non‐isch.                    |                                                                                                                          |                                                                                                           | 1 year                                                           |
|    |                                                             |                                                                             |                       |                                           |                                                                                                                          |                                                                                                           |                                                                  |
|    |                                                             |                                                                             |                       | 29% (2/7) in isch.                        |                                                                                                                          |                                                                                                           |                                                                  |
|    |                                                             |                                                                             |                       |                                           |                                                                                                                          |                                                                                                           |                                                                  |
|    |                                                             |                                                                             | 8 x isch.             |                                           |                                                                                                                          |                                                                                                           |                                                                  |
+----+-------------------------------------------------------------+-----------------------------------------------------------------------------+-----------------------+-------------------------------------------+--------------------------------------------------------------------------------------------------------------------------+-----------------------------------------------------------------------------------------------------------+------------------------------------------------------------------+
| 4  | Narang et al.[51](#sct312634-bib-0051){ref-type="ref"}      | SLET ×1                                                                     | 1                     | 100% (1/1)                                | Unchanged ×1                                                                                                             | Cataract                                                                                                  | 31 months                                                        |
+----+-------------------------------------------------------------+-----------------------------------------------------------------------------+-----------------------+-------------------------------------------+--------------------------------------------------------------------------------------------------------------------------+-----------------------------------------------------------------------------------------------------------+------------------------------------------------------------------+
| 5  | Mednick et al.[55](#sct312634-bib-0055){ref-type="ref"}     | Pterygium surgery + adjunct mitomycin C treatment                           | 4                     | 100% (4/4)                                | 100% (4/4)                                                                                                               | Symblepharon ×1                                                                                           | 8‐30 months                                                      |
|    |                                                             |                                                                             |                       |                                           |                                                                                                                          |                                                                                                           |                                                                  |
|    |                                                             |                                                                             |                       |                                           |                                                                                                                          | Pterygium in new area ×1                                                                                  |                                                                  |
|    |                                                             |                                                                             |                       |                                           |                                                                                                                          |                                                                                                           |                                                                  |
|    |                                                             |                                                                             |                       |                                           |                                                                                                                          | Neovascularization resolved with anti‐VEGF injections ×1                                                  |                                                                  |
+----+-------------------------------------------------------------+-----------------------------------------------------------------------------+-----------------------+-------------------------------------------+--------------------------------------------------------------------------------------------------------------------------+-----------------------------------------------------------------------------------------------------------+------------------------------------------------------------------+
| 6  | Gupta et al.[28](#sct312634-bib-0028){ref-type="ref"}       | Repeated SLET ×1 resulted in failure                                        | 30                    | Partial 66.6% (10/15) Total 73.3% (11/15) | 71.4 % of patients                                                                                                       | Progressive conjunctivalization (30%)                                                                     | 1.1 years (range, 6 months‐3.5 years)                            |
|    |                                                             |                                                                             |                       |                                           |                                                                                                                          |                                                                                                           |                                                                  |
|    |                                                             | PK ×3                                                                       |                       |                                           | BCVA at presentation: 20/200 or worse (blindness) ×24                                                                    | Foreign body sensation in donor eye (×3; 10%)                                                             |                                                                  |
|    |                                                             |                                                                             |                       |                                           |                                                                                                                          |                                                                                                           |                                                                  |
|    |                                                             |                                                                             |                       |                                           | 20/70‐20/160 (low vision) ×2                                                                                             |                                                                                                           |                                                                  |
|    |                                                             |                                                                             |                       |                                           |                                                                                                                          |                                                                                                           |                                                                  |
|    |                                                             |                                                                             |                       |                                           | 20/60 or better ×4                                                                                                       |                                                                                                           |                                                                  |
|    |                                                             |                                                                             |                       |                                           |                                                                                                                          |                                                                                                           |                                                                  |
|    |                                                             |                                                                             |                       |                                           | Final BCVA: 20/200 or worse (blindness) ×19                                                                              |                                                                                                           |                                                                  |
|    |                                                             |                                                                             |                       |                                           |                                                                                                                          |                                                                                                           |                                                                  |
|    |                                                             |                                                                             |                       |                                           |                                                                                                                          |                                                                                                           |                                                                  |
|    |                                                             |                                                                             |                       |                                           |                                                                                                                          |                                                                                                           |                                                                  |
|    |                                                             |                                                                             |                       |                                           | 20/70‐20/160 (low vision) ×2                                                                                             |                                                                                                           |                                                                  |
|    |                                                             |                                                                             |                       |                                           |                                                                                                                          |                                                                                                           |                                                                  |
|    |                                                             |                                                                             |                       |                                           | 20/60 or better ×9                                                                                                       |                                                                                                           |                                                                  |
+----+-------------------------------------------------------------+-----------------------------------------------------------------------------+-----------------------+-------------------------------------------+--------------------------------------------------------------------------------------------------------------------------+-----------------------------------------------------------------------------------------------------------+------------------------------------------------------------------+
| 7  | Basu et al.[29](#sct312634-bib-0029){ref-type="ref"}        | PK ×1                                                                       | 30                    | 80% (24/30)                               | 63% of successful outcomes (15/24)                                                                                       | Recurrence of LSCD ×6 (20%)                                                                               | 2.3 ± 1.5 years                                                  |
|    |                                                             |                                                                             |                       |                                           |                                                                                                                          |                                                                                                           |                                                                  |
|    |                                                             | Corneal transplantation ×4                                                  |                       |                                           | Improved to 20/200 or better                                                                                             | Hemorrhage beneath the AM ×2 (7%)                                                                         |                                                                  |
|    |                                                             |                                                                             |                       |                                           |                                                                                                                          |                                                                                                           |                                                                  |
|    |                                                             | Repeated SLET ×2                                                            |                       |                                           |                                                                                                                          | Persistent epithelial defect with corneal graft infiltrate ×1 (3%)                                        |                                                                  |
|    |                                                             |                                                                             |                       |                                           |                                                                                                                          |                                                                                                           |                                                                  |
|    |                                                             |                                                                             |                       |                                           |                                                                                                                          | Donor eye: Subconjunctival hemorrhage ×6 (20 %)                                                           |                                                                  |
+----+-------------------------------------------------------------+-----------------------------------------------------------------------------+-----------------------+-------------------------------------------+--------------------------------------------------------------------------------------------------------------------------+-----------------------------------------------------------------------------------------------------------+------------------------------------------------------------------+
| 8  | Singh et al.[32](#sct312634-bib-0032){ref-type="ref"}       | DALK 9‐15 months after SLET ×11                                             | 11                    | 82% (9/11)                                | 64% (7/11)                                                                                                               | Recurrence of keratolimbal vascularization or conjunctivalization with graft opacification ×2             | 11.63 ± 2.21 months                                              |
|    |                                                             |                                                                             |                       |                                           |                                                                                                                          |                                                                                                           |                                                                  |
|    |                                                             |                                                                             |                       |                                           | Improvement by ≥2 lines                                                                                                  | Focal recurrences of mild keratolimbal conjunctivalization/vascularization ×9                             |                                                                  |
|    |                                                             |                                                                             |                       |                                           |                                                                                                                          |                                                                                                           |                                                                  |
|    |                                                             |                                                                             |                       |                                           |                                                                                                                          | Mid‐to‐deep stromal involvement with visual axis opacification ×9                                         |                                                                  |
|    |                                                             |                                                                             |                       |                                           |                                                                                                                          |                                                                                                           |                                                                  |
|    |                                                             |                                                                             |                       |                                           |                                                                                                                          | Deeper stromal involvement of varying degrees which did not involve the visual axis ×2                    |                                                                  |
+----+-------------------------------------------------------------+-----------------------------------------------------------------------------+-----------------------+-------------------------------------------+--------------------------------------------------------------------------------------------------------------------------+-----------------------------------------------------------------------------------------------------------+------------------------------------------------------------------+
| 9  | Vasquez‐Perez[38](#sct312634-bib-0038){ref-type="ref"}      | PK                                                                          | 1                     | 100% (1/1)                                | 100% (1/1)                                                                                                               | Recurrence of herpes simplex keratitis ×1                                                                 | \>20 months                                                      |
|    |                                                             |                                                                             |                       |                                           |                                                                                                                          |                                                                                                           |                                                                  |
|    |                                                             |                                                                             |                       |                                           | From hand movements to 6/12                                                                                              |                                                                                                           |                                                                  |
+----+-------------------------------------------------------------+-----------------------------------------------------------------------------+-----------------------+-------------------------------------------+--------------------------------------------------------------------------------------------------------------------------+-----------------------------------------------------------------------------------------------------------+------------------------------------------------------------------+
| 10 | Mohamed et al.[39](#sct312634-bib-0039){ref-type="ref"}     |                                                                             | 1                     | 100% (1/1)                                | 100% (1/1)                                                                                                               | Focal LSCD and recurrence of symblepharon ×1                                                              | 18 months                                                        |
|    |                                                             |                                                                             |                       |                                           |                                                                                                                          |                                                                                                           |                                                                  |
|    |                                                             |                                                                             |                       |                                           | 20/160 improved to 20/40 vision                                                                                          | Recurrence of granulation tissue ×1                                                                       |                                                                  |
+----+-------------------------------------------------------------+-----------------------------------------------------------------------------+-----------------------+-------------------------------------------+--------------------------------------------------------------------------------------------------------------------------+-----------------------------------------------------------------------------------------------------------+------------------------------------------------------------------+
| 11 | Kaliki et al.[35](#sct312634-bib-0035){ref-type="ref"}      | Wide excisional biopsy of OSSN + Primary SLET ×7                            | 7                     | Clear cornea: 71.4% (5/7)                 |                                                                                                                          | Peripheral corneal opacity ×2 (29%)                                                                       | 12 months                                                        |
|    |                                                             |                                                                             |                       |                                           |                                                                                                                          |                                                                                                           |                                                                  |
|    |                                                             | Plaque radiotherapy×3                                                       |                       |                                           |                                                                                                                          |                                                                                                           |                                                                  |
+----+-------------------------------------------------------------+-----------------------------------------------------------------------------+-----------------------+-------------------------------------------+--------------------------------------------------------------------------------------------------------------------------+-----------------------------------------------------------------------------------------------------------+------------------------------------------------------------------+
| 12 | Arora et al.[33](#sct312634-bib-0033){ref-type="ref"}       |                                                                             | 10 SLET               | 100% (20/20)                              | 100% (20/20)                                                                                                             | SLET group:                                                                                               | 6 months                                                         |
|    |                                                             |                                                                             |                       |                                           |                                                                                                                          |                                                                                                           |                                                                  |
|    |                                                             |                                                                             | 10 CLAU               |                                           | Preoperative in SLET group was 2.13 ± 1.0, which improved to 1.53 ± 0.72 and 1.62 ± 0.86 at 3 and 6 months, respectively | Hemorrhage under AM ×1                                                                                    |                                                                  |
|    |                                                             |                                                                             |                       |                                           |                                                                                                                          |                                                                                                           |                                                                  |
|    |                                                             |                                                                             |                       |                                           |                                                                                                                          | (Spontaneous resolution)                                                                                  |                                                                  |
|    |                                                             |                                                                             |                       |                                           |                                                                                                                          |                                                                                                           |                                                                  |
|    |                                                             |                                                                             |                       |                                           |                                                                                                                          | No complications at donor site in either group                                                            |                                                                  |
+----+-------------------------------------------------------------+-----------------------------------------------------------------------------+-----------------------+-------------------------------------------+--------------------------------------------------------------------------------------------------------------------------+-----------------------------------------------------------------------------------------------------------+------------------------------------------------------------------+
| 13 | Iyer et al.[30](#sct312634-bib-0030){ref-type="ref"}        | AlloSLET                                                                    | 17                    | 94.11% (17/18)                            | 72.2% (13/18)                                                                                                            | Gradual failure of allograft ×7                                                                           | 10.28 ± 6.7 (3‐23) months                                        |
|    |                                                             |                                                                             |                       |                                           |                                                                                                                          |                                                                                                           |                                                                  |
|    |                                                             | Subsequent limbal autograft (SLET technique) ×5                             | (18 eyes)             |                                           | Better than 20/120                                                                                                       | Symblepharon formation ×3 (16.7 %)                                                                        |                                                                  |
+----+-------------------------------------------------------------+-----------------------------------------------------------------------------+-----------------------+-------------------------------------------+--------------------------------------------------------------------------------------------------------------------------+-----------------------------------------------------------------------------------------------------------+------------------------------------------------------------------+
| 14 | Basu et al.[3](#sct312634-bib-0003){ref-type="ref"}         | Standard SLET + modified for partial LSCD ×125                              | 125                   | 76% (95/125) overall                      | 75.2% (94/125) overall                                                                                                   | Donor eye:                                                                                                | 1.5 years (range, 1‐4 years)                                     |
|    |                                                             |                                                                             |                       |                                           |                                                                                                                          |                                                                                                           |                                                                  |
|    |                                                             | PK ×10                                                                      |                       | Adults---Tot. 80% (44/55)                 | Two‐line improvement                                                                                                     | Subconjunctival hemorrhage ×35 (28%)                                                                      |                                                                  |
|    |                                                             |                                                                             |                       |                                           |                                                                                                                          |                                                                                                           |                                                                  |
|    |                                                             | Cataract surgery ×5                                                         |                       | Adults---Part. 80% (8/10)                 |                                                                                                                          | Pyogenic granuloma ×2 (1.6%)                                                                              |                                                                  |
|    |                                                             |                                                                             |                       |                                           |                                                                                                                          |                                                                                                           |                                                                  |
|    |                                                             |                                                                             |                       | Children---Tot. 71.2% (37/52)             |                                                                                                                          | LSCD ×0                                                                                                   |                                                                  |
|    |                                                             |                                                                             |                       |                                           |                                                                                                                          |                                                                                                           |                                                                  |
|    |                                                             |                                                                             |                       | Children---Part. 76% (6/8)                |                                                                                                                          | Recipient eye: Conjunctivalization ×23 (18.4 %)                                                           |                                                                  |
|    |                                                             |                                                                             |                       |                                           |                                                                                                                          |                                                                                                           |                                                                  |
|    |                                                             |                                                                             |                       |                                           |                                                                                                                          | Symblepharon ×21 (16.8%)                                                                                  |                                                                  |
|    |                                                             |                                                                             |                       |                                           |                                                                                                                          |                                                                                                           |                                                                  |
|    |                                                             |                                                                             |                       |                                           |                                                                                                                          | Hemorrhage under hAM ×10 (8%)                                                                             |                                                                  |
|    |                                                             |                                                                             |                       |                                           |                                                                                                                          |                                                                                                           |                                                                  |
|    |                                                             |                                                                             |                       |                                           |                                                                                                                          | Loss of transplants ×7 (5.6%)                                                                             |                                                                  |
|    |                                                             |                                                                             |                       |                                           |                                                                                                                          |                                                                                                           |                                                                  |
|    |                                                             |                                                                             |                       |                                           |                                                                                                                          | Detached hAM ×4 (3.2 %)                                                                                   |                                                                  |
|    |                                                             |                                                                             |                       |                                           |                                                                                                                          |                                                                                                           |                                                                  |
|    |                                                             |                                                                             |                       |                                           |                                                                                                                          | Keratitis ×8 (6.4 %)                                                                                      |                                                                  |
|    |                                                             |                                                                             |                       |                                           |                                                                                                                          |                                                                                                           |                                                                  |
|    |                                                             |                                                                             |                       |                                           |                                                                                                                          | Corneal melting with perforation ×2 (1.6 %)                                                               |                                                                  |
|    |                                                             |                                                                             |                       |                                           |                                                                                                                          |                                                                                                           |                                                                  |
|    |                                                             |                                                                             |                       |                                           |                                                                                                                          | Lignocaine allergy ×1 (0.8 %)                                                                             |                                                                  |
+----+-------------------------------------------------------------+-----------------------------------------------------------------------------+-----------------------+-------------------------------------------+--------------------------------------------------------------------------------------------------------------------------+-----------------------------------------------------------------------------------------------------------+------------------------------------------------------------------+
| 15 | Arya et al.[40](#sct312634-bib-0040){ref-type="ref"}        | Standard + cadaveric AlloSLET                                               | 2                     | 100% (2/2)                                | 100% (2/2)                                                                                                               | Case 2: underlying optic atrophy                                                                          | 3 months                                                         |
|    |                                                             |                                                                             |                       |                                           |                                                                                                                          |                                                                                                           |                                                                  |
|    |                                                             |                                                                             |                       |                                           | Case 1: From HM to 20/20 by six weeks                                                                                    |                                                                                                           |                                                                  |
|    |                                                             |                                                                             |                       |                                           |                                                                                                                          |                                                                                                           |                                                                  |
|    |                                                             |                                                                             |                       |                                           | Case 2: From light perception to hand movements close to the face                                                        |                                                                                                           |                                                                  |
+----+-------------------------------------------------------------+-----------------------------------------------------------------------------+-----------------------+-------------------------------------------+--------------------------------------------------------------------------------------------------------------------------+-----------------------------------------------------------------------------------------------------------+------------------------------------------------------------------+
| 16 | Queiroz et al.[36](#sct312634-bib-0036){ref-type="ref"}     |                                                                             | 4                     | 50% (2/4)                                 | 25% (1/4)                                                                                                                | No adhesion of limbal grafts to cornea ×1                                                                 | 6 months                                                         |
|    |                                                             |                                                                             |                       |                                           |                                                                                                                          |                                                                                                           |                                                                  |
|    |                                                             |                                                                             |                       |                                           | From hand motion to 20/80 vision                                                                                         | Recurrence of corneal neovascularization and persistent epithelial defect ×1                              |                                                                  |
+----+-------------------------------------------------------------+-----------------------------------------------------------------------------+-----------------------+-------------------------------------------+--------------------------------------------------------------------------------------------------------------------------+-----------------------------------------------------------------------------------------------------------+------------------------------------------------------------------+
| 17 | Vazirani et al.[27](#sct312634-bib-0027){ref-type="ref"}    |                                                                             | 68                    | 83.8% (57/68)                             | 64.7% (44/68)                                                                                                            | Focal recurrences of pannus not progressing to the center of the cornea ×21 (30.9%)                       | \>6 months. Median, 12 months. Range, 6‐59 months                |
|    |                                                             |                                                                             |                       |                                           |                                                                                                                          |                                                                                                           |                                                                  |
|    |                                                             |                                                                             |                       |                                           | 20/200 or better                                                                                                         | Microbial keratitis ×5                                                                                    |                                                                  |
|    |                                                             |                                                                             |                       |                                           |                                                                                                                          |                                                                                                           |                                                                  |
|    |                                                             |                                                                             |                       |                                           |                                                                                                                          | Ocular hypertension secondary to steroid use ×1                                                           |                                                                  |
|    |                                                             |                                                                             |                       |                                           |                                                                                                                          |                                                                                                           |                                                                  |
|    |                                                             |                                                                             |                       |                                           |                                                                                                                          | Pyogenic granuloma ×1                                                                                     |                                                                  |
|    |                                                             |                                                                             |                       |                                           |                                                                                                                          |                                                                                                           |                                                                  |
|    |                                                             |                                                                             |                       |                                           |                                                                                                                          | Focal iatrogenic LSCD at the site of the donor limbus ×1                                                  |                                                                  |
+----+-------------------------------------------------------------+-----------------------------------------------------------------------------+-----------------------+-------------------------------------------+--------------------------------------------------------------------------------------------------------------------------+-----------------------------------------------------------------------------------------------------------+------------------------------------------------------------------+
| 18 | Mittal et al.[41](#sct312634-bib-0041){ref-type="ref"}      | Excisional biopsy of cornea/limbus + SLET in same setting                   | 1                     | 100 % (1/1)                               | 100% (1/1)                                                                                                               | None                                                                                                      | 2 years                                                          |
|    |                                                             |                                                                             |                       |                                           |                                                                                                                          |                                                                                                           |                                                                  |
|    |                                                             | Radiotherapy                                                                |                       |                                           | From 20/50 to 20/40                                                                                                      |                                                                                                           |                                                                  |
+----+-------------------------------------------------------------+-----------------------------------------------------------------------------+-----------------------+-------------------------------------------+--------------------------------------------------------------------------------------------------------------------------+-----------------------------------------------------------------------------------------------------------+------------------------------------------------------------------+
| 19 | Mittal et al.[52](#sct312634-bib-0052){ref-type="ref"}      | Repeated SLET with conjunctival autograft ×3                                | 4                     | 100% (4/4)                                | 100% (4/4)                                                                                                               | LSCD focal recurrence with symblepharon ×3                                                                | 12‐60 months after first SLET and 13‐36 months after repeat SLET |
|    |                                                             |                                                                             |                       |                                           |                                                                                                                          |                                                                                                           |                                                                  |
|    |                                                             |                                                                             |                       |                                           | From PLPR to counting fingers close to face ×1                                                                           |                                                                                                           |                                                                  |
|    |                                                             |                                                                             |                       |                                           |                                                                                                                          |                                                                                                           |                                                                  |
|    |                                                             |                                                                             |                       |                                           | From PR to 6/36 x 2                                                                                                      |                                                                                                           |                                                                  |
|    |                                                             |                                                                             |                       |                                           |                                                                                                                          |                                                                                                           |                                                                  |
|    |                                                             |                                                                             |                       |                                           | From HM to 6/18 x 1                                                                                                      |                                                                                                           |                                                                  |
+----+-------------------------------------------------------------+-----------------------------------------------------------------------------+-----------------------+-------------------------------------------+--------------------------------------------------------------------------------------------------------------------------+-----------------------------------------------------------------------------------------------------------+------------------------------------------------------------------+
| 20 | Vazirani et al.[42](#sct312634-bib-0042){ref-type="ref"}    | Customized SLET for treating focal recurrent conjunctivalization after SLET | 1                     | 100% (1/1)                                | 100% (1/1)                                                                                                               | Focal recurrences of conjunctivalization on the cornea and recurrence of symblepharon after first SLET ×1 | 5 months                                                         |
|    |                                                             |                                                                             |                       |                                           |                                                                                                                          |                                                                                                           |                                                                  |
|    |                                                             |                                                                             |                       |                                           | From light perception to 20/50                                                                                           |                                                                                                           |                                                                  |
+----+-------------------------------------------------------------+-----------------------------------------------------------------------------+-----------------------+-------------------------------------------+--------------------------------------------------------------------------------------------------------------------------+-----------------------------------------------------------------------------------------------------------+------------------------------------------------------------------+
| 21 | Nair et al.[43](#sct312634-bib-0043){ref-type="ref"}        | Cataract surgery                                                            | 1                     | 100% (1/1)                                | 100% (1/1)                                                                                                               | Recurrence LSCD ×1                                                                                        | 7 months                                                         |
|    |                                                             |                                                                             |                       |                                           |                                                                                                                          |                                                                                                           |                                                                  |
|    |                                                             |                                                                             |                       |                                           | From light perception to 20/60                                                                                           |                                                                                                           |                                                                  |
+----+-------------------------------------------------------------+-----------------------------------------------------------------------------+-----------------------+-------------------------------------------+--------------------------------------------------------------------------------------------------------------------------+-----------------------------------------------------------------------------------------------------------+------------------------------------------------------------------+
| 22 | Bogantes[34](#sct312634-bib-0034){ref-type="ref"}           | Pterygium surgery + SLET                                                    | 10 eyes in 9 patients | 100% (10/10)                              |                                                                                                                          | Pyogenic granuloma at the junction of AM and conjunctiva ×1                                               | 8 months                                                         |
+----+-------------------------------------------------------------+-----------------------------------------------------------------------------+-----------------------+-------------------------------------------+--------------------------------------------------------------------------------------------------------------------------+-----------------------------------------------------------------------------------------------------------+------------------------------------------------------------------+
| 23 | Das et al.[44](#sct312634-bib-0044){ref-type="ref"}         |                                                                             | 1                     | 100% (1/1)                                | 100% (1/1)                                                                                                               |                                                                                                           | 27 months                                                        |
|    |                                                             |                                                                             |                       |                                           |                                                                                                                          |                                                                                                           |                                                                  |
|    |                                                             |                                                                             |                       |                                           | From counting fingers at 1m to 20/50                                                                                     |                                                                                                           |                                                                  |
+----+-------------------------------------------------------------+-----------------------------------------------------------------------------+-----------------------+-------------------------------------------+--------------------------------------------------------------------------------------------------------------------------+-----------------------------------------------------------------------------------------------------------+------------------------------------------------------------------+
| 24 | Mittal et al.[4](#sct312634-bib-0004){ref-type="ref"}       |                                                                             | 5                     | 100% (5/5)                                | 80% (3/5)                                                                                                                | SPK ×2                                                                                                    | 10.8 months (range, 8‐36 months)                                 |
|    |                                                             |                                                                             |                       |                                           |                                                                                                                          |                                                                                                           |                                                                  |
|    |                                                             |                                                                             |                       |                                           | 2 line improvement                                                                                                       | Resolved after increasing lubricant                                                                       |                                                                  |
+----+-------------------------------------------------------------+-----------------------------------------------------------------------------+-----------------------+-------------------------------------------+--------------------------------------------------------------------------------------------------------------------------+-----------------------------------------------------------------------------------------------------------+------------------------------------------------------------------+
| 25 | Amescua et al.[37](#sct312634-bib-0037){ref-type="ref"}     |                                                                             | 4                     | 100% (4/4)                                | 100% (4/4)                                                                                                               |                                                                                                           | 7.5 ± 1.3 months                                                 |
|    |                                                             |                                                                             |                       |                                           |                                                                                                                          |                                                                                                           |                                                                  |
|    |                                                             |                                                                             |                       |                                           | From worse than 20/200 to 20/50 or better                                                                                |                                                                                                           |                                                                  |
+----+-------------------------------------------------------------+-----------------------------------------------------------------------------+-----------------------+-------------------------------------------+--------------------------------------------------------------------------------------------------------------------------+-----------------------------------------------------------------------------------------------------------+------------------------------------------------------------------+
| 26 | Vazirani et al.[45](#sct312634-bib-0045){ref-type="ref"}    | Conjunctival autografting with supplemental SLET ×1                         | 1                     | 100% (1/1)                                | 100% (1/1)                                                                                                               | Recurrence of LSCD with symblepharon and forniceal shortening ×1                                          | 6 months                                                         |
|    |                                                             |                                                                             |                       |                                           |                                                                                                                          |                                                                                                           |                                                                  |
|    |                                                             |                                                                             |                       |                                           | From light perception to 20/40                                                                                           |                                                                                                           |                                                                  |
+----+-------------------------------------------------------------+-----------------------------------------------------------------------------+-----------------------+-------------------------------------------+--------------------------------------------------------------------------------------------------------------------------+-----------------------------------------------------------------------------------------------------------+------------------------------------------------------------------+
| 27 | Lal et al.[46](#sct312634-bib-0046){ref-type="ref"}         |                                                                             | 1                     | 100% (1/1)                                | 100% (1/1)                                                                                                               |                                                                                                           | 2 years                                                          |
|    |                                                             |                                                                             |                       |                                           |                                                                                                                          |                                                                                                           |                                                                  |
|    |                                                             |                                                                             |                       |                                           | From 20/50 to 20/25                                                                                                      |                                                                                                           |                                                                  |
+----+-------------------------------------------------------------+-----------------------------------------------------------------------------+-----------------------+-------------------------------------------+--------------------------------------------------------------------------------------------------------------------------+-----------------------------------------------------------------------------------------------------------+------------------------------------------------------------------+
| 28 | Bhalekar et al.[47](#sct312634-bib-0047){ref-type="ref"}    |                                                                             | 1                     | 100% (1/1)                                | 100% (1/1)                                                                                                               | Allograft rejection managed with aggressive immune suppression                                            | 6 months                                                         |
|    |                                                             |                                                                             |                       |                                           |                                                                                                                          |                                                                                                           |                                                                  |
|    |                                                             |                                                                             |                       |                                           | From hand motions to 20/100                                                                                              |                                                                                                           |                                                                  |
+----+-------------------------------------------------------------+-----------------------------------------------------------------------------+-----------------------+-------------------------------------------+--------------------------------------------------------------------------------------------------------------------------+-----------------------------------------------------------------------------------------------------------+------------------------------------------------------------------+
| 29 | Bhalekar et al.[48](#sct312634-bib-0048){ref-type="ref"}    |                                                                             | 1                     | 100% (1/1)                                | 100% (1/1)                                                                                                               |                                                                                                           | 13 months                                                        |
|    |                                                             |                                                                             |                       |                                           |                                                                                                                          |                                                                                                           |                                                                  |
|    |                                                             |                                                                             |                       |                                           | Improved to 20/80                                                                                                        |                                                                                                           |                                                                  |
+----+-------------------------------------------------------------+-----------------------------------------------------------------------------+-----------------------+-------------------------------------------+--------------------------------------------------------------------------------------------------------------------------+-----------------------------------------------------------------------------------------------------------+------------------------------------------------------------------+
| 30 | Bhalekar et al.[49](#sct312634-bib-0049){ref-type="ref"}    |                                                                             | 1                     |                                           | 100% (1/1)                                                                                                               | Whitish plaque and corneal epithelial hyperplasia ×1                                                      | 3 weeks                                                          |
|    |                                                             |                                                                             |                       |                                           |                                                                                                                          |                                                                                                           |                                                                  |
|    |                                                             |                                                                             |                       |                                           | From light perception with accurate projection to 20/200                                                                 |                                                                                                           |                                                                  |
+----+-------------------------------------------------------------+-----------------------------------------------------------------------------+-----------------------+-------------------------------------------+--------------------------------------------------------------------------------------------------------------------------+-----------------------------------------------------------------------------------------------------------+------------------------------------------------------------------+
| 31 | Sangwan et al.[2](#sct312634-bib-0002){ref-type="ref"}      | Original SLET protocol                                                      | 6                     | 100% (6/6)                                | 66.6% (4/6)                                                                                                              |                                                                                                           | 9.2 ± 1.9 months                                                 |
|    |                                                             |                                                                             |                       |                                           |                                                                                                                          |                                                                                                           |                                                                  |
|    |                                                             |                                                                             |                       |                                           | From worse than 20/200 in all recipient eyes to 20/40 or better in four eyes                                             |                                                                                                           |                                                                  |
+----+-------------------------------------------------------------+-----------------------------------------------------------------------------+-----------------------+-------------------------------------------+--------------------------------------------------------------------------------------------------------------------------+-----------------------------------------------------------------------------------------------------------+------------------------------------------------------------------+

Abbreviations: AMT, amniotic membrane transplantation; BCVA, best corrected visual acuity; CLET, cultivated limbal epithelial transplantation; DALK, deep anterior lamellar keratoplasty; HM, hand movements; ISCH, ischemia; LSCD, limbal stem cell deficiency; LSCT, limbal stem cell transplantation; MMC, mitomycin C; OSSN, ocular surface squamous neoplasia; Part., partial LSCD; PK, penetrating keratoplasty; PLPR, hand motions, accurate projection of rays; SLET, simple limbal epithelial transplantation; SPK, superficial punctuate keratitis; Tot., total LSCD.

The overall success rate compares well with other procedures that use autologous limbal tissue.[7](#sct312634-bib-0007){ref-type="ref"}, [9](#sct312634-bib-0009){ref-type="ref"}, [17](#sct312634-bib-0017){ref-type="ref"} A direct comparison between SLET and CLAU performed on patients with the same etiology and in the same clinical setting supports SLET as an equally safe and effective treatment for LSCD.[33](#sct312634-bib-0033){ref-type="ref"} A primary success rate of 62.5% (n = 30) was also reported where SLET was performed in cases of failed CLET.[29](#sct312634-bib-0029){ref-type="ref"}

The success rate declined in treatment of pediatric patients with LSCD, with a rate of 71% compared with 85.5% in adults.[3](#sct312634-bib-0003){ref-type="ref"}, [28](#sct312634-bib-0028){ref-type="ref"}, [52](#sct312634-bib-0052){ref-type="ref"} Successful treatment of pediatric LSCD using CLET has also been disappointing (46.7%),[61](#sct312634-bib-0061){ref-type="ref"} suggesting pediatric LSCD is especially challenging. This could be linked to the pressure for young patients to undergo surgery earlier (before inflammation is fully controlled) in order to reduce the risk of developing amblyopia (lazy eye),[28](#sct312634-bib-0028){ref-type="ref"} which often accompanies sensory vision loss. Furthermore, ocular inflammation is correlated with failure[62](#sct312634-bib-0062){ref-type="ref"} and children generally experience more inflammation.[63](#sct312634-bib-0063){ref-type="ref"}

Overall, SLET compares well with other procedures (CLAU, CLET, COMET) that use autologous tissue for treatment of LSCD, resulting in similar average primary and secondary criteria success rates. Importantly, SLET has now been validated in several larger studies and in several international centers since the first published report in 2012.[3](#sct312634-bib-0003){ref-type="ref"}, [27](#sct312634-bib-0027){ref-type="ref"}, [28](#sct312634-bib-0028){ref-type="ref"}, [29](#sct312634-bib-0029){ref-type="ref"} Many studies have reported long‐term success, with follow‐up periods of 12 to 59 months (Tables [1](#sct312634-tbl-0001){ref-type="table"} and 2).[3](#sct312634-bib-0003){ref-type="ref"}, [27](#sct312634-bib-0027){ref-type="ref"}, [28](#sct312634-bib-0028){ref-type="ref"}, [30](#sct312634-bib-0030){ref-type="ref"}, [35](#sct312634-bib-0035){ref-type="ref"}, [38](#sct312634-bib-0038){ref-type="ref"}, [39](#sct312634-bib-0039){ref-type="ref"}

8. RISK FACTORS FOR FAILURE AND COMPLICATIONS {#sct312634-sec-0011}
=============================================

8.1. Preoperative {#sct312634-sec-0012}
-----------------

The presenting features of the patient eye should be considered when deciding treatment. Absolute contraindications include a dry ocular surface, blind eye with no visual potential, disorganized anterior segment, and the continued presence of adnexal pathologies.[23](#sct312634-bib-0023){ref-type="ref"} Presentation with LSCD resulting from acid injury is also correlated with failure.[28](#sct312634-bib-0028){ref-type="ref"} The association of presenting features with prognosis post‐SLET has been summarized in a review by Shanbhag et al. (see their table 1[23](#sct312634-bib-0023){ref-type="ref"}).

Preexisting symblepharon is correlated with failure.[3](#sct312634-bib-0003){ref-type="ref"}, [27](#sct312634-bib-0027){ref-type="ref"}, [28](#sct312634-bib-0028){ref-type="ref"} According to Basu et al., the presence of symblepharon extending toward the cornea pre‐SLET could indicate conjunctival deficiency, and outcomes may improve if symblepharon is addressed before or at the time of SLET.[3](#sct312634-bib-0003){ref-type="ref"} A retrospective case series of four children where only one patient had a completely successful outcome also noted that recurrence of LSCD coincided with areas of severe preoperative symblepharon.[52](#sct312634-bib-0052){ref-type="ref"} The three partial success patients had initially presented with more severe injury and extensive LSCD. Thus, authors suggested that damage to conjunctival stem cells may have contributed to failure. Repeat SLET combined with conjunctival autograft transplant resulted in reepithelialization and an avascular surface.

Optimization of the ocular surface including fast resolution of inflammation prior to SLET is important to give the best chance for successful outcome, especially in pediatric cases.[3](#sct312634-bib-0003){ref-type="ref"}, [27](#sct312634-bib-0027){ref-type="ref"}, [52](#sct312634-bib-0052){ref-type="ref"} Glucocorticoids and AM transfer are often used to reduce inflammation in the acute phase and induce epithelization. Iyer and colleagues have shown that alloSLET can also be successfully used for this purpose.[30](#sct312634-bib-0030){ref-type="ref"}

8.2. Intraoperative {#sct312634-sec-0013}
-------------------

Based on poor results when combining PK with CLET, Basu and colleagues recommend identifying patients with thin corneas by optical coherence tomography or ultrasound bio‐microscopy before surgery so that lamellar corneal graft can be performed simultaneously with SLET if required.[3](#sct312634-bib-0003){ref-type="ref"}, [64](#sct312634-bib-0064){ref-type="ref"}

8.3. Postoperative {#sct312634-sec-0014}
------------------

The most common complications following SLET reported in the three largest follow‐up studies (involving 125,[3](#sct312634-bib-0003){ref-type="ref"} 68,[27](#sct312634-bib-0027){ref-type="ref"} and 30[28](#sct312634-bib-0028){ref-type="ref"} patients) were focal recurrence of LSCD,[27](#sct312634-bib-0027){ref-type="ref"} progressive conjunctivalization,[3](#sct312634-bib-0003){ref-type="ref"}, [28](#sct312634-bib-0028){ref-type="ref"} progressive symblepharon,[3](#sct312634-bib-0003){ref-type="ref"} and keratitis (Table [1](#sct312634-tbl-0001){ref-type="table"}).[3](#sct312634-bib-0003){ref-type="ref"}, [27](#sct312634-bib-0027){ref-type="ref"} More unusual complications were loss of transplants following surgery,[3](#sct312634-bib-0003){ref-type="ref"} epithelial defects that persisted for more than 6 months,[29](#sct312634-bib-0029){ref-type="ref"}, [36](#sct312634-bib-0036){ref-type="ref"} and pyogenic granuloma.[3](#sct312634-bib-0003){ref-type="ref"}, [27](#sct312634-bib-0027){ref-type="ref"}, [34](#sct312634-bib-0034){ref-type="ref"}

One study reported corneal epithelial hyperplasia following SLET in an 11‐year‐old boy.[49](#sct312634-bib-0049){ref-type="ref"} The authors suggested that in young patients the contact lens should be removed as soon as possible after corneal epithelialization is complete due to the high rate of cell proliferation that is typically seen.

A trial of 30 patients who underwent SLET after failed CLET reported zero cases of iatrogenic LSCD despite harvest of multiple biopsies from donor eyes.[29](#sct312634-bib-0029){ref-type="ref"} Harmless subconjunctival hemorrhage after biopsy harvest, which resolved within 1 month was noted in 28% of donor eyes in the largest study involving 125 patients.[3](#sct312634-bib-0003){ref-type="ref"} Iatrogenic LSCD at the site of the donor limbus was also noted in one patient.

In summary, preexisting symblepharon and simultaneous performance of PK with SLET are the main features correlated with SLET failure. Complications following SLET are relatively benign and manageable. The risk of iatrogenic LSCD at the donor site is also low even after harvest of multiple biopsies for repeat SLET.

9. ALLOGENIC SLET {#sct312634-sec-0015}
=================

Very little has been published on the use of alloSLET for permanent restoration of the cornea for treatment of bilateral LSCD. Bilateral LSCD often occurs secondary to Stevens‐Johnson syndrome, mucous membrane phemigoid (MMP), and severe chemical burns, which produce extensive cicatrization or dryness making patients unsuitable candidates for treatment with SLET.[23](#sct312634-bib-0023){ref-type="ref"} A total of 56 eyes in six separate studies have used alloSLET.[23](#sct312634-bib-0023){ref-type="ref"}, [30](#sct312634-bib-0030){ref-type="ref"}, [38](#sct312634-bib-0038){ref-type="ref"}, [40](#sct312634-bib-0040){ref-type="ref"}, [47](#sct312634-bib-0047){ref-type="ref"}, [50](#sct312634-bib-0050){ref-type="ref"} Immunosuppressant steroids were prescribed topically (19 eyes[30](#sct312634-bib-0030){ref-type="ref"}, [38](#sct312634-bib-0038){ref-type="ref"}), systemically (1 eye[47](#sct312634-bib-0047){ref-type="ref"}), or in combination (30 eyes[23](#sct312634-bib-0023){ref-type="ref"}). Transplant rejection can be managed by increasing the dose of systemic and topical immunosuppressants.[23](#sct312634-bib-0023){ref-type="ref"}, [47](#sct312634-bib-0047){ref-type="ref"} A total of 30 eyes were treated in the largest alloSLET study reported so far; 16 eyes received living‐related donor tissue and 14 eyes of 13 patients received cadaveric donor tissue.[23](#sct312634-bib-0023){ref-type="ref"} At the final follow‐up (median 28 months), the overall improvement in visual acuity was from hand‐motion to 20/60 in more than 60% of eyes. Achievement of a stable corneal surface indicating successful outcome varied slightly between the two groups with success noted in 14 of 16 (87.5%) eyes receiving living‐related SLET and in 11 of 14 (78.6%) eyes in the cadaveric group at the final follow‐up (average 28 months). No serious systemic complications were noted. These results compare well with typical results using lr‐CLAL and KLAL techniques, for example, in a large retrospective case series 105 of 136 patients (77.2%) achieved ocular surface stability.[24](#sct312634-bib-0024){ref-type="ref"}

Iyer et al. investigated the effectiveness of alloSLET in management of acute inflammation in 17 patients (18 eyes) with severe grade 4 or worse chemical injury (Dua\'s classification).[30](#sct312634-bib-0030){ref-type="ref"} Ten of the patients were children with an age range of 3 months to 10 years. Systemic immunosuppressants were not used since later rejection of allogenic transplants was expected. Follow‐up ranged from 3 to 23 months. The authors performed alloSLET with the intention of aiding fast epithelialization of the denuded cornea and to promote early reconstruction of the corneal surface and not with an aim toward long‐term survival of the allogenic cells (Figure [S2](#sct312634-supitem-0001){ref-type="supplementary-material"}). They speculated that the small size of the allogenic explants may have reduced the antigenic load leading to slow rejection. Complete reepithelialization was achieved within 10‐40 days in 17 of 18 (94%) eyes. Improved visual acuity was seen in 13 of 17 (76%) patients. Symblepharon involving one or two quadrants was noted in three eyes.

Iyer and colleagues hypothesize that early resolution of inflammation facilitated by the use of AM and topical steroids may have been influential in preventing further damage to residual stem cells.[30](#sct312634-bib-0030){ref-type="ref"} Furthermore, early reepithelialization by allogenic explants may have also reduced ocular surface inflammation allowing residual stem cells to repopulate the cornea.

Though studies are so far limited, reports suggest that use of AM in the alloSLET procedure and regeneration of an epithelial layer using allogenic explants quietens inflammation on the ocular surface. Therefore, in addition to offering an alternative treatment for bilateral LSCD, alloSLET may be especially applicable for fast temporary treatment of pediatric patients, where inflammation has been reported as a key factor hindering successful outcome. AlloSLET offers the advantage of quickly restoring a clear epithelial layer, albeit of a temporary nature, which aids in improvement in visual acuity as early as a month following injury.[30](#sct312634-bib-0030){ref-type="ref"} Thus, the risk of amblyopia can be reduced or addressed earlier in pediatric patients. Importantly, the use of allogeneic tissue as a temporary application maintains an undisturbed healthy alternate eye. Valuable autologous limbal tissue can then later be harvested for use in SLET once inflammation in the injured eye has subsided, giving a higher chance of success.

10. FUTURE STUDIES {#sct312634-sec-0016}
==================

The AM carrier could be a critical factor to the success of SLET. It contains anti‐inflammatory cytokines, growth factors, and provides a substrate that may allow stem cells in SLET explants to embed. SLET results may be further improved with the use of cross‐linked AM.[65](#sct312634-bib-0065){ref-type="ref"} Comparison of the effect of using denuded vs. intact AM would also be useful. Consideration of a standardized synthetic replacement for AM could also be evaluated to eliminate the inherent variability found in AM, a natural tissue.

Cumulative results show that although regeneration of the corneal epithelium occurs in 83.5% of SLET operations, visual acuity is improved in only 68.7% of patients (Table [1](#sct312634-tbl-0001){ref-type="table"}). Avenues for improvement include the pursuit of work indicating that inflammation plays a key role in SLET operations with poor outcomes.[3](#sct312634-bib-0003){ref-type="ref"} Inflammatory state may be influenced by the time between injury and operation, as reported in several studies.[3](#sct312634-bib-0003){ref-type="ref"}, [28](#sct312634-bib-0028){ref-type="ref"}, [62](#sct312634-bib-0062){ref-type="ref"} To advance the treatment of LSCD in children, it may be necessary to focus on faster resolution of inflammation before SLET.[28](#sct312634-bib-0028){ref-type="ref"} Temporary application of alloSLET may accomplish this, and larger studies are needed to confirm.[30](#sct312634-bib-0030){ref-type="ref"}

Mittal et al. showed that individual explants from the same donor often vary in outgrowth.[4](#sct312634-bib-0004){ref-type="ref"} Follow‐up studies could optimize the amount of fibrin glue used for mounting explants, as well as limbal explant size, orientation, harvest site, and handling techniques.

Although SLET minimizes the amount of biopsy harvested from the donor eye, the same technique using an alternative source of autologous tissue may have the additional benefit of offering treatment of bilateral LSCD. Oral mucosal tissue has proved effective in treating LSCD transplanted as cultured sheet transplants (COMET).[15](#sct312634-bib-0015){ref-type="ref"}, [66](#sct312634-bib-0066){ref-type="ref"} Transfer of small oral mucosal biopsies in a simple oral mucosal epithelial transplantation (SOMET) technique would avoid the need to harvest ocular limbal material altogether.

Direct comparison of the effectiveness of CLAU, CLET, and SLET in a large randomized prospective study would be useful.

11. CONCLUSION {#sct312634-sec-0017}
==============

In conclusion, results so far indicate that SLET offers a comparable alternative to CLAU and CLET using the two main criteria for success: corneal re‐epithelialization and improvement in visual acuity. In addition, there are advantages to harvesting a smaller biopsy for transplant, such as lowered risk of iatrogenic LSCD and the option for repeat operations. Importantly, harvest and transplantation are accomplished in a single operation, which increases efficiency, promotes accessibility, and reduces cost. Latest work shows limbal allografts can be used successfully in treatment of bilateral LSCD.

Direct transfer of limbal explants may support superior maintenance of stem cell phenotype and function following transplant. On the other hand, analysis of biopsies used for CLET transplants has shown a correlation between clinical success and stem cell content suggesting stem cells are maintained during culture.[67](#sct312634-bib-0067){ref-type="ref"} The opportunity for gene editing prior to transplantation may also be an important advantage of the CLET technique.

Long‐term follow‐up studies equivalent to CLAU and CLET are now becoming available, and results using SLET are promising. AlloSLET used as a temporary treatment to resolve initial inflammation and quickly recover an intact epithelial layer also holds great potential. This may be especially important in treating pediatric cases of LSCD. Avenues for improvement should be further explored, including the feasibility of using non‐limbal autologous tissue from the oral cavity for treatment of bilateral LSCD (SOMET).
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